Ramesh Arora, MD
Cardiovascular Disease (Cardiology) · Van Nuys
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 46 years
- Graduated 1980
Offices
1 location · Ramesh Arora Medical Corp · 3 clinicians in this group
Looking this up.
Hospitals listed: Cedars-Sinai Medical Center · Valley Presbyterian Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Arora’s office at (818) 994-0616 to ask if they take your plan before you enroll.
California Medical Board record
Licence C42324 · Current
Licensed to practise in California · since 1987 · expires 2028-06-30 · University of Delhi, College of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Cedars-Sinai Medical CenterLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Postoperative sepsis rate: 7.77 (6.11 to 9.44) · 6,132 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.2 to 14.7) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 134.15 (109.33 to 158.98) · 557 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.386, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.661, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.628, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.503, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.8 (3 to 4.8) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.8) · 2,580 cases, Jan 2024 – Dec 2024
- Valley Presbyterian HospitalVan Nuys, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.049, Oct 2024 – Sep 2025
See every measure and the patient survey for Cedars-Sinai Medical Center
Behind the star rating — Deaths: 7 better, 1 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 7.77 (6.11 to 9.44) · 6,132 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.2 to 14.7) · 1,174 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.15 (109.33 to 158.98) · 557 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.386 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.661 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.628 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.503 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.8 (3 to 4.8) · 1,174 cases | Better | Jan 2024 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.8) · 2,580 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.66 (0.06 to 1.25) · 8,257 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.92 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 223 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.9 · 191 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.3 · 409 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.5 · 1,544 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.5 · 1,742 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 549 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.3 · 9,504 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.28) · 29,170 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.05 to 0.32) · 31,661 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.1 (3.06 to 5.14) · 11,199 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0.47 to 2.29) · 6,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (1.24 to 2.86) · 10,075 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.2 (5.76 to 10.65) · 6,012 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.91 (0.72 to 3.11) · 2,803 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.75 (0.47 to 1.03) · 27,865 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 472 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.437 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.168 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 492 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 1,750 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.9 · 498 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5.8 · 1,908 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.7 · 1,850 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 1,572 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.7 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 172 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 240 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.1 to 17.5) · 1,197 cases | No different | Jan 2022 – Dec 2024 |
What patients said (1,081 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Valley Presbyterian Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.049 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0 to 2.02) · 594 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.48 to 1.25) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.9 (96.19 to 217.61) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 53 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 79 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 216 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 325 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 15.1 · 70 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 1,116 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 3,518 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,606 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.27 (0.88 to 5.65) · 646 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 217 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.04 (0.42 to 3.66) · 635 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.41 (0 to 16.47) · 226 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.87 (0.68 to 9.06) · 208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 125 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1.24) · 3,088 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 89 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.574 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.06 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.874 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.935 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 271 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 83.7 · 85 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 59.4 · 264 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.7 · 360 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 359 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.2 to 17) · 88 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 56 cases | No different | Jan 2024 – Dec 2024 |
What patients said (397 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 1 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 66% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 61% |
| Doctors "always" listened carefully | 66% |
| Doctors "always" treated them with courtesy and respect | 72% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 66% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 76% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$1,152,188
Medicare paid this office $1,152,188 for 578 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 186 | $342,548 | $1,842 |
| Short return visit (20+ min) | 535 | $169,654 | $83 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 187 | $164,257 | $442 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 420 | $80,869 | $189 |
| Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | 479 | $58,131 | $50 |
See all 25 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 186 | $342,548 | $1,842 |
| Short return visit (20+ min) | 535 | $169,654 | $83 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 187 | $164,257 | $442 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 420 | $80,869 | $189 |
| Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | 479 | $58,131 | $50 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 65 | $53,338 | $821 |
| Ultrasound of both sides of head and neck blood flow | 282 | $52,099 | $185 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 476 | $28,704 | $22 |
| Return visit (30+ min) | 176 | $27,908 | $114 |
| Ultrasound of leg arteries or artery grafts | 103 | $24,430 | $237 |
| Nuclear medicine study of heart muscle blood flow by pet | 186 | $24,334 | $131 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 114 | $21,231 | $185 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 60 | $15,225 | $254 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 221 | $14,890 | $67 |
| New patient visit (45+ min) | 90 | $13,371 | $149 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 32 | $12,492 | $390 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 442 | $11,287 | $13 |
| Ultrasound of arm arteries or artery grafts | 45 | $8,782 | $195 |
| Injection of drug or substance into vein | 208 | $7,514 | $36 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 84 | $5,330 | $63 |
| Injection, regadenoson, 0.1 mg | 218 | $4,717 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 31 | $2,774 | $45 |
| Long return visit (40+ min) | 17 | $2,418 | $142 |
| Insertion of needle into vein for collection of blood sample | 118 | $1,522 | $9 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 63 | $1,413 | $22 |
Who their Medicare patients are
578 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 12% · Women 59% · Also on Medicaid 94% · Health risk score 1.62. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 63% · Coronary heart disease 62% · Depression 41% · Heart failure 37% · Chronic kidney disease 30% · COPD 25% · Dementia 20% · Atrial fibrillation 17% · Cancer 11% · Stroke 9%.
The office billed $3,631,070, Medicare allowed $1,434,207 and paid $1,152,188; for 9,307 services of 33 kinds; $4,717 of it was for drugs given in the office and $1,147,471 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 578 | 9,307 | 73 | 1.62 | $3,631,070 | $1,152,188 |
| 2023 | 581 | 7,256 | 73 | 1.79 | $2,948,720 | $886,172 |
| 2022 | 632 | 9,344 | 73 | 1.82 | $2,932,475 | $759,069 |
| 2021 | 654 | 6,956 | 72 | 1.98 | $2,620,105 | $600,549 |
| 2020 | 605 | 4,320 | 73 | 2.29 | $1,749,535 | $376,621 |
| 2019 | 941 | 6,956 | 73 | 2.51 | $2,829,900 | $602,601 |
| 2018 | 957 | 7,225 | 74 | 2.65 | $2,898,600 | $623,172 |
| 2017 | 954 | 6,657 | 73 | 2.78 | $2,617,460 | $582,653 |
| 2016 | 679 | 12,030 | 73 | 2.21 | $2,377,766 | $506,856 |
| 2015 | 653 | 8,430 | 74 | 2.53 | $1,394,635 | $351,776 |
| 2014 | 1,206 | 17,963 | 73 | 2.86 | $2,948,655 | $716,742 |
| 2013 | 1,818 | 11,625 | 74 | 2.76 | $4,190,105 | $1,091,860 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 25 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 159 | $277,116 | $1,743 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 159 | $132,698 | $417 |
| Short return visit (20+ min) | 523 | $110,777 | $77 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 421 | $75,943 | $179 |
| Ultrasound of both sides of head and neck blood flow | 271 | $48,592 | $178 |
| Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | 439 | $33,896 | $37 |
| Injection, regadenoson, 0.1 mg | 180 | $31,158 | None |
| Return visit (30+ min) | 182 | $27,816 | $111 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 473 | $22,433 | $21 |
| Nuclear medicine study of heart muscle blood flow by pet | 159 | $19,799 | $125 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 89 | $16,031 | $178 |
| Ultrasound of leg arteries or artery grafts | 64 | $14,199 | $222 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 180 | $11,332 | $63 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 13 | $10,484 | $806 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 157 | $9,822 | $63 |
| New patient visit (45+ min) | 59 | $8,197 | $137 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $8,018 | $382 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 399 | $7,040 | $13 |
| Injection of drug or substance into vein | 175 | $5,974 | $34 |
| Ultrasound of arm arteries or artery grafts | 21 | $3,876 | $185 |
| Long return visit (40+ min) | 23 | $3,424 | $149 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 23 | $2,192 | $49 |
| Ultrasound scan of abdominal aorta | 14 | $1,762 | $126 |
| Insertion of needle into vein for collection of blood sample | 64 | $596 | $8 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 13 | $284 | $22 |
2022: 28 services
| Short return visit (20+ min) | 573 | $174,132 | $78 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 419 | $76,666 | $180 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 154 | $64,228 | $417 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 283 | $60,674 | $42 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 30 | $50,564 | $1,685 |
| Ultrasound of both sides of head and neck blood flow | 242 | $44,178 | $183 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 246 | $43,146 | $47 |
| Injection, regadenoson, 0.1 mg | 180 | $35,147 | None |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 30 | $24,929 | $415 |
| Return visit (30+ min) | 152 | $23,896 | $111 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 480 | $21,922 | $21 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 97 | $17,913 | $181 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 19 | $16,341 | $860 |
| Ultrasound of leg arteries or artery grafts | 66 | $15,239 | $231 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 154 | $14,801 | $48 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 183 | $10,843 | $58 |
| New patient visit (45+ min) | 72 | $9,955 | $138 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 144 | $9,588 | $66 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 309 | $5,373 | $12 |
| Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | 104 | $4,126 | $39 |
| Nuclear medicine study of heart muscle blood flow by pet | 30 | $3,674 | $122 |
| Long return visit (40+ min) | 25 | $3,467 | $139 |
| Ultrasound of arm arteries or artery grafts | 14 | $2,646 | $189 |
| Injection of drug or substance into vein | 48 | $1,773 | $37 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 14 | $1,502 | $36 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 68 | $634 | $9 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 19 | $425 | $22 |
| Insertion of needle into vein for collection of blood sample | 91 | $326 | $3 |
2021: 24 services
| Short return visit (20+ min) | 598 | $171,466 | $81 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 200 | $89,611 | $448 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 449 | $83,821 | $185 |
| Ultrasound of both sides of head and neck blood flow | 247 | $47,130 | $190 |
| Injection, regadenoson, 0.1 mg | 198 | $36,466 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 186 | $32,231 | $88 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 517 | $22,556 | $20 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 91 | $17,294 | $184 |
| Ultrasound of leg arteries or artery grafts | 59 | $14,437 | $245 |
| Return visit (30+ min) | 104 | $14,026 | $120 |
| New patient visit (45+ min) | 80 | $11,950 | $149 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 205 | $11,838 | $57 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 15 | $10,214 | $681 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 139 | $9,460 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 341 | $5,512 | $13 |
| Long return visit (40+ min) | 30 | $4,730 | $158 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 27 | $2,926 | $29 |
| Ultrasound of arm arteries or artery grafts | 13 | $2,568 | $198 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 101 | $2,353 | $18 |
| Injection of drug or substance into vein | 55 | $2,077 | $38 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 28 | $1,689 | $60 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 28 | $1,290 | $46 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 15 | $340 | $23 |
| Insertion of needle into vein for collection of blood sample | 91 | $321 | $3 |
2020: 21 services
| Short return visit (20+ min) | 428 | $77,676 | $65 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 336 | $63,752 | $189 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 121 | $51,903 | $425 |
| Ultrasound of both sides of head and neck blood flow | 162 | $30,296 | $185 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 120 | $22,573 | $98 |
| Injection, regadenoson, 0.1 mg | 113 | $20,004 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 401 | $15,859 | $21 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 76 | $14,363 | $184 |
| Return visit (30+ min) | 109 | $12,997 | $96 |
| Ultrasound of leg arteries or artery grafts | 52 | $12,390 | $238 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $7,452 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 123 | $7,024 | $57 |
| New patient visit (45+ min) | 48 | $6,266 | $131 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 74 | $5,783 | $75 |
| Injection of drug or substance into vein | 85 | $3,092 | $36 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 161 | $2,936 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,265 | $174 |
| Short return visit | 42 | $1,727 | $39 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 15 | $955 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $809 | $62 |
| Insertion of needle into vein for collection of blood sample | 54 | $188 | $3 |
2019: 24 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 499 | $95,879 | $187 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 208 | $91,325 | $439 |
| Short return visit (20+ min) | 512 | $86,628 | $64 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 219 | $40,916 | $96 |
| Ultrasound of both sides of head and neck blood flow | 207 | $38,698 | $186 |
| Injection, regadenoson, 0.1 mg | 200 | $35,555 | None |
| Return visit (30+ min) | 255 | $35,507 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 153 | $29,661 | $90 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 120 | $22,435 | $181 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 571 | $20,963 | $20 |
| Ultrasound of leg arteries or artery grafts | 69 | $16,397 | $238 |
| New patient visit (45+ min) | 95 | $12,843 | $135 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 203 | $11,540 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $9,937 | $174 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 13 | $8,759 | $626 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 118 | $8,740 | $73 |
| Injection of drug or substance into vein | 218 | $7,770 | $35 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 342 | $7,652 | $15 |
| Long return visit (40+ min) | 20 | $2,572 | $129 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 23 | $1,472 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,066 | $63 |
| Insertion of needle into vein for collection of blood sample | 103 | $370 | $3 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 13 | $294 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 11 | $110 | $7 |
2018: 23 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 239 | $104,495 | $435 |
| Short return visit (20+ min) | 504 | $87,577 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 440 | $83,870 | $185 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 242 | $45,126 | $95 |
| Ultrasound of both sides of head and neck blood flow | 230 | $43,314 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 212 | $40,088 | $89 |
| Injection, regadenoson, 0.1 mg | 201 | $35,107 | None |
| Ultrasound study of arm or leg veins with compression and maneuvers | 161 | $28,782 | $178 |
| Return visit (30+ min) | 183 | $21,925 | $91 |
| Ultrasound of leg arteries or artery grafts | 85 | $20,418 | $240 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 507 | $19,364 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 229 | $12,858 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 73 | $12,762 | $172 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 136 | $10,574 | $76 |
| Injection of drug or substance into vein | 235 | $9,871 | $42 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 369 | $9,000 | $14 |
| New patient visit (45+ min) | 67 | $8,951 | $134 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 11 | $8,222 | $685 |
| New patient visit (60+ min) | 48 | $7,925 | $165 |
| Long return visit (40+ min) | 47 | $5,832 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $2,168 | $62 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 11 | $267 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 16 | $158 | $7 |
2017: 22 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 233 | $98,868 | $421 |
| Short return visit (20+ min) | 475 | $80,091 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 359 | $73,508 | $203 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 271 | $52,166 | $89 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 235 | $44,913 | $95 |
| Injection, regadenoson, 0.1 mg | 212 | $36,667 | None |
| Ultrasound of both sides of head and neck blood flow | 185 | $33,770 | $182 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 104 | $18,219 | $175 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $17,369 | $170 |
| Return visit (30+ min) | 143 | $15,701 | $90 |
| Ultrasound of leg arteries or artery grafts | 64 | $15,201 | $238 |
| New patient visit (60+ min) | 91 | $15,117 | $166 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 435 | $13,875 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 212 | $12,699 | $59 |
| Injection of drug or substance into vein | 229 | $12,168 | $52 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 117 | $8,964 | $75 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 321 | $7,256 | $15 |
| Long return visit (40+ min) | 53 | $6,653 | $121 |
| New patient visit (45+ min) | 24 | $3,258 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $2,210 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,510 | $116 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 15 | $151 | $7 |
2016: 23 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 242 | $99,299 | $275 |
| Short return visit (20+ min) | 438 | $79,266 | $62 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 247 | $46,562 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 219 | $44,438 | $203 |
| Ultrasound of both sides of head and neck blood flow | 201 | $34,618 | $170 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 152 | $26,321 | $166 |
| Injection, regadenoson, 0.1 mg | 109 | $18,038 | None |
| Ultrasound of leg arteries or artery grafts | 90 | $15,708 | $171 |
| Return visit (30+ min) | 131 | $15,603 | $90 |
| Injection of drug or substance into vein | 240 | $14,922 | $51 |
| New patient visit (60+ min) | 72 | $12,425 | $173 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 381 | $11,669 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 157 | $9,194 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $8,721 | $88 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 322 | $7,903 | $15 |
| Long return visit (40+ min) | 52 | $6,947 | $124 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 74 | $5,801 | $73 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,400 | $169 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 20 | $5,390 | $106 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 120 | $3,990 | None |
| New patient visit (45+ min) | 30 | $3,927 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,160 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 11 | $86 | $7 |
2015: 25 services
| Short return visit (20+ min) | 396 | $67,939 | $62 |
| Ultrasound of both sides of head and neck blood flow | 274 | $50,137 | $182 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 105 | $42,453 | $397 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 160 | $29,058 | $177 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 104 | $27,481 | $132 |
| Return visit (30+ min) | 211 | $26,534 | $88 |
| Ultrasound of leg arteries or artery grafts | 98 | $20,204 | $206 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 81 | $16,411 | $203 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 369 | $9,810 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 351 | $9,635 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $9,435 | $87 |
| New patient visit (60+ min) | 44 | $7,599 | $173 |
| Long return visit (40+ min) | 55 | $6,090 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,612 | $172 |
| Injection, regadenoson, 0.1 mg | 18 | $3,139 | None |
| New patient visit (45+ min) | 24 | $3,066 | $128 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 80 | $2,902 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 48 | $2,748 | $57 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $1,734 | $72 |
| Injection of drug or substance into vein | 13 | $721 | $51 |
| Short return visit | 11 | $383 | $35 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 38 | $331 | $7 |
| Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes | 13 | $244 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 20 | $159 | $7 |
| Insertion of needle into vein for collection of blood sample | 11 | $35 | $3 |
2014: 28 services
| Short return visit (20+ min) | 538 | $114,516 | $61 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 66 | $83,407 | $1,245 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 383 | $78,750 | $201 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 350 | $67,562 | $87 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 156 | $66,572 | $427 |
| Ultrasound of both sides of head and neck blood flow | 258 | $44,474 | $170 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 156 | $40,884 | $131 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 70 | $31,755 | $228 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 144 | $25,808 | $170 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 175 | $23,619 | None |
| Ultrasound study of arm or leg veins with compression and maneuvers | 103 | $17,577 | $167 |
| Return visit (30+ min) | 165 | $17,428 | $88 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 466 | $14,294 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 212 | $12,502 | $58 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 157 | $11,788 | $71 |
| Long return visit (40+ min) | 84 | $11,314 | $120 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 370 | $10,793 | $14 |
| Ultrasound of leg arteries or artery grafts | 52 | $10,708 | $206 |
| New patient visit (60+ min) | 64 | $10,416 | $163 |
| Injection, regadenoson, 0.1 mg | 41 | $6,690 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $3,438 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 58 | $3,179 | $54 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 154 | $1,559 | $7 |
| Measurement of heart blood flow and respiration | 42 | $1,171 | $22 |
| Short return visit | 27 | $1,055 | $34 |
| Injection of drug or substance into vein | 21 | $1,053 | $50 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 35 | $300 | $7 |
| Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes | 13 | $258 | $15 |
2013: 30 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 252 | $259,270 | $1,017 |
| Short return visit (20+ min) | 659 | $150,273 | $60 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 255 | $118,083 | $229 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 372 | $81,756 | $84 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 424 | $70,608 | $165 |
| Ultrasound of both sides of head and neck blood flow | 334 | $55,086 | $164 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 245 | $54,662 | None |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 73 | $32,531 | $446 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 167 | $29,472 | $164 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 141 | $24,231 | $167 |
| Return visit (30+ min) | 200 | $22,479 | $88 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 292 | $19,867 | $67 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 74 | $19,396 | $132 |
| Ultrasound of leg arteries or artery grafts | 112 | $19,063 | $170 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 559 | $18,012 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 506 | $17,154 | $15 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 207 | $15,779 | $74 |
| Injection of drug or substance into vein | 263 | $13,710 | $51 |
| Injection, regadenoson, 0.1 mg | 78 | $13,186 | None |
| Long return visit (40+ min) | 100 | $12,614 | $117 |
| New patient visit (60+ min) | 74 | $11,689 | $158 |
| Measurement of heart blood flow and respiration | 183 | $6,742 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 653 | $6,147 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 94 | $4,920 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 77 | $4,539 | $58 |
| New patient visit (45+ min) | 14 | $1,900 | $136 |
| Short return visit | 34 | $1,464 | $38 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 49 | $540 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 20 | $459 | $22 |
| Insertion of needle into vein for collection of blood sample | 12 | $44 | $3 |
Medicaid work
$366,370 in 2024
Medicaid paid $366,370 for 8,694 billed services this clinician did in 2024, up to 270 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 666 | $90,651 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 222 | $70,070 |
| Short return visit (20+ min) | 2,562 | $38,892 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 299 | $22,691 |
| CARDIOVASCULAR STRESS TEST | 331 | $17,038 |
| Tc99m sestamibi | 174 | $17,030 |
| External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional | 38 | $16,199 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 901 | $13,829 |
| XTRNL ECG REC<48 HRS RECORDING SCAN A/R R&I | 192 | $12,721 |
| OFF/OP EST MAY X REQ PHY/QHP | 1,693 | $12,484 |
| New patient visit (45+ min) | 193 | $11,082 |
| EXTREMITY STUDY | 99 | $9,403 |
| 2024 | 8,694 | 21 | 270 | $366,370 |
| 2023 | 9,588 | 19 | 272 | $439,099 |
| 2022 | 12,035 | 18 | 358 | $353,495 |
| 2021 | 10,423 | 15 | 314 | $347,822 |
| 2020 | 8,766 | 18 | 291 | $253,012 |
| 2019 | 13,500 | 18 | 310 | $391,962 |
| 2018 | 11,930 | 18 | 234 | $200,118 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 956 | $123,940 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 235 | $61,818 |
| Short return visit (20+ min) | 2,289 | $48,442 |
| OFF/OP EST MAY X REQ PHY/QHP | 2,023 | $29,699 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 369 | $26,689 |
| Injection, regadenoson, 0.1 mg | 305 | $25,646 |
| XTRNL ECG REC<48 HRS RECORDING SCAN A/R R&I | 347 | $21,053 |
| Tc99m sestamibi | 228 | $19,988 |
| CARDIOVASCULAR STRESS TEST | 399 | $16,548 |
| New patient visit (45+ min) | 319 | $16,449 |
| Return visit (30+ min) | 466 | $11,246 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 760 | $10,418 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 892 | $69,212 |
| Short return visit (20+ min) | 3,829 | $62,109 |
| OFF/OP EST MAY X REQ PHY/QHP | 1,971 | $47,037 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 309 | $46,878 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 379 | $17,168 |
| Tc99m sestamibi | 309 | $16,430 |
| Injection, regadenoson, 0.1 mg | 340 | $16,080 |
| XTRNL ECG REC<48 HRS RECORDING SCAN A/R R&I | 350 | $11,345 |
| CARDIOVASCULAR STRESS TEST | 463 | $10,514 |
| Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days | 461 | $10,443 |
| New patient visit (45+ min) | 298 | $10,383 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 696 | $9,527 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 925 | $71,475 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 336 | $60,373 |
| Short return visit (20+ min) | 3,475 | $57,470 |
| OFF/OP EST MAY X REQ PHY/QHP | 2,001 | $53,000 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 327 | $18,327 |
| XTRNL ECG REC<48 HRS RECORDING SCAN A/R R&I | 365 | $13,958 |
| New patient visit (45+ min) | 315 | $13,173 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug | 295 | $12,328 |
| Injection, regadenoson, 0.1 mg | 349 | $12,296 |
| CARDIOVASCULAR STRESS TEST | 512 | $10,125 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 840 | $10,031 |
| Tc99m sestamibi | 343 | $7,139 |
2020
| OFF/OP EST MAY X REQ PHY/QHP | 1,762 | $56,103 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 834 | $48,096 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 286 | $41,052 |
| Short return visit (20+ min) | 2,495 | $38,385 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug | 290 | $12,959 |
| CARDIOVASCULAR STRESS TEST | 453 | $10,260 |
| New patient visit (45+ min) | 320 | $9,999 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 274 | $9,086 |
| XTRNL ECG REC<48 HRS RECORDING SCAN A/R R&I | 323 | $7,011 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 703 | $6,022 |
| Injection, regadenoson, 0.1 mg | 228 | $3,639 |
| Tc99m sestamibi | 295 | $2,966 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 1,274 | $83,357 |
| OFF/OP EST MAY X REQ PHY/QHP | 2,429 | $66,280 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 440 | $58,988 |
| Short return visit (20+ min) | 3,121 | $48,247 |
| New patient visit (45+ min) | 680 | $23,320 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug | 351 | $17,055 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 1,901 | $13,835 |
| XTRNL ECG REC<48 HRS RECORDING SCAN A/R R&I | 414 | $13,770 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 329 | $13,347 |
| CARDIOVASCULAR STRESS TEST | 645 | $11,408 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 388 | $9,165 |
| EXTREMITY STUDY | 204 | $8,785 |
2018
| Short return visit (20+ min) | 2,799 | $43,783 |
| OFF/OP EST MAY X REQ PHY/QHP | 2,096 | $43,508 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 927 | $28,659 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 488 | $23,080 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug | 506 | $17,192 |
| Injection, regadenoson, 0.1 mg | 340 | $7,474 |
| New patient visit (45+ min) | 295 | $5,273 |
| EXTREMITY STUDY | 209 | $4,389 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 1,604 | $4,293 |
| CARDIOVASCULAR STRESS TEST | 586 | $3,930 |
| Return visit (30+ min) | 330 | $3,828 |
| Tc99m sestamibi | 504 | $3,630 |
Drugs they prescribed that Part D paid
$387,579
Pharmacies billed $387,579 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
6,851 generic and 525 brand-name prescriptions · $387,579 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 176 | $170,810 | $971 |
| Entresto | 62 | $73,721 | $1,189 |
| Vascepa | 47 | $17,564 | $374 |
| Brilinta | 32 | $14,089 | $440 |
| Ranolazine Er | 171 | $12,907 | $75 |
See all 59 drugs
| Eliquis | 176 | $170,810 | $971 |
| Entresto | 62 | $73,721 | $1,189 |
| Vascepa | 47 | $17,564 | $374 |
| Brilinta | 32 | $14,089 | $440 |
| Ranolazine Er | 171 | $12,907 | $75 |
| Nitroglycerin | 725 | $11,925 | $16 |
| Metoprolol | 716 | $5,679 | $8 |
| Isosorbide Mononitrate Er | 527 | $3,965 | $8 |
| Fenofibrate | 19 | $3,154 | $166 |
| Icosapent Ethyl | 21 | $2,546 | $121 |
| Propranolol | 171 | $2,382 | $14 |
| Rosuvastatin | 316 | $2,268 | $7 |
| Cilostazol | 184 | $2,200 | $12 |
| Hydralazine | 268 | $2,167 | $8 |
| Atorvastatin | 453 | $2,110 | $5 |
| Nifedipine Er | 97 | $2,028 | $21 |
| Ezetimibe | 135 | $1,451 | $11 |
| Olmesartan-Hydrochlorothiazide | 53 | $1,280 | $24 |
| Omega-3 Acid Ethyl Esters | 22 | $1,278 | $58 |
| Valsartan-Hydrochlorothiazide | 46 | $1,211 | $26 |
| Carvedilol | 313 | $1,082 | $3 |
| Losartan-Hydrochlorothiazide | 135 | $1,077 | $8 |
| Losartan | 225 | $1,068 | $5 |
| Amlodipine Besylate-Benazepril | 126 | $1,012 | $8 |
| Amlodipine Besylate | 417 | $959 | $2 |
| Lisinopril | 148 | $910 | $6 |
| Clonidine | 265 | $819 | $3 |
| Clopidogrel | 122 | $733 | $6 |
| Amlodipine-Valsartan | 18 | $727 | $40 |
| Benazepril | 120 | $706 | $6 |
| Metoprolol | 194 | $688 | $4 |
| Amiodarone | 24 | $608 | $25 |
| Isosorbide Dinitrate | 15 | $528 | $35 |
| Valsartan | 40 | $512 | $13 |
| Irbesartan-Hydrochlorothiazide | 24 | $451 | $19 |
| Flecainide Acetate | 17 | $445 | $26 |
| Potassium Chloride | 18 | $423 | $23 |
| Diltiazem 24hr Er (Cd) | 14 | $393 | $28 |
| Olmesartan Medoxomil | 59 | $382 | $6 |
| Amlodipine-Olmesartan | 12 | $356 | $30 |
| Midodrine | 11 | $350 | $32 |
| Propranolol Hcl Er | 13 | $316 | $24 |
| Fenofibrate | 30 | $301 | $10 |
| Digoxin | 15 | $299 | $20 |
| Verapamil Er | 19 | $271 | $14 |
| Irbesartan | 32 | $259 | $8 |
| Furosemide | 110 | $248 | $2 |
| Diltiazem | 14 | $194 | $14 |
| Simvastatin | 65 | $191 | $3 |
| Enalapril Maleate | 32 | $189 | $6 |
| Pravastatin | 53 | $163 | $3 |
| Ramipril | 53 | $161 | $3 |
| Chlorthalidone | 17 | $127 | $7 |
| Atenolol | 31 | $120 | $4 |
| Doxazosin Mesylate | 16 | $119 | $7 |
| Hydrochlorothiazide | 91 | $119 | $1 |
| Felodipine Er | 12 | $83 | $7 |
| Meclizine | 22 | $82 | $4 |
| Spironolactone | 20 | $64 | $3 |
Year by year
| 2024 | 7,376 | 620 | None | 7% | $387,579 |
| 2023 | 6,203 | 576 | 0% (0) | 9% | $507,489 |
| 2022 | 3,657 | 507 | 0% (0) | None | $267,862 |
| 2021 | 2,113 | 362 | 0% (0) | None | $138,634 |
| 2020 | 1,429 | 214 | 0% (0) | 12% | $85,075 |
| 2019 | 3,348 | 370 | 0% (0) | 14% | $220,225 |
| 2018 | 6,665 | 538 | 0% (0) | None | $437,880 |
| 2017 | 5,943 | 493 | None | 18% | $420,626 |
| 2016 | 4,768 | 445 | None | 25% | $340,814 |
| 2015 | 3,753 | 384 | None | 30% | $267,867 |
| 2014 | 3,010 | 337 | None | 30% | $184,049 |
| 2013 | 3,398 | 369 | 0% (0) | 33% | $206,093 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 56 drugs
| Eliquis | 154 | $147,659 | $959 |
| Entresto | 63 | $86,008 | $1,365 |
| Ranolazine Er | 212 | $39,171 | $185 |
| Vascepa | 45 | $20,372 | $453 |
| Brilinta | 29 | $17,101 | $590 |
| Nitroglycerin | 409 | $15,604 | $38 |
| Metoprolol | 650 | $13,459 | $21 |
| Isosorbide Mononitrate Er | 377 | $10,769 | $29 |
| Rosuvastatin | 294 | $9,221 | $31 |
| Atorvastatin | 436 | $8,718 | $20 |
| Repatha Sureclick | 12 | $8,456 | $705 |
| Ezetimibe | 105 | $5,849 | $56 |
| Amlodipine Besylate | 341 | $5,307 | $16 |
| Omega-3 Acid Ethyl Esters | 23 | $4,926 | $214 |
| Cilostazol | 118 | $4,740 | $40 |
| Carvedilol | 280 | $4,719 | $17 |
| Benicar | 13 | $4,710 | $362 |
| Propranolol | 166 | $4,709 | $28 |
| Olmesartan-Hydrochlorothiazide | 74 | $4,329 | $58 |
| Hydralazine | 210 | $3,821 | $18 |
| Losartan | 179 | $3,714 | $21 |
| Nifedipine Er | 75 | $3,325 | $44 |
| Metoprolol | 193 | $3,031 | $16 |
| Amlodipine Besylate-Benazepril | 125 | $2,755 | $22 |
| Olmesartan Medoxomil | 79 | $2,730 | $35 |
| Clonidine | 151 | $2,377 | $16 |
| Losartan-Hydrochlorothiazide | 85 | $2,327 | $27 |
| Clonidine | 18 | $2,204 | $122 |
| Valsartan-Hydrochlorothiazide | 36 | $2,191 | $61 |
| Benazepril | 125 | $2,182 | $17 |
| Lisinopril | 154 | $2,152 | $14 |
| Fenofibrate | 54 | $1,880 | $35 |
| Clopidogrel | 88 | $1,845 | $21 |
| Irbesartan | 49 | $1,501 | $31 |
| Irbesartan-Hydrochlorothiazide | 31 | $1,193 | $38 |
| Enalapril Maleate | 41 | $1,066 | $26 |
| Diltiazem 24hr Er (Cd) | 23 | $977 | $42 |
| Ramipril | 57 | $954 | $17 |
| Atenolol | 41 | $840 | $20 |
| Propranolol Hcl Er | 12 | $765 | $64 |
| Simvastatin | 39 | $715 | $18 |
| Telmisartan | 13 | $700 | $54 |
| Furosemide | 89 | $588 | $7 |
| Potassium Chloride | 23 | $580 | $25 |
| Fenofibrate | 25 | $567 | $23 |
| Diltiazem | 18 | $480 | $27 |
| Chlorthalidone | 19 | $447 | $24 |
| Amiodarone | 23 | $423 | $18 |
| Doxazosin Mesylate | 16 | $370 | $23 |
| Digoxin | 11 | $358 | $33 |
| Pravastatin | 17 | $344 | $20 |
| Hydrochlorothiazide | 82 | $289 | $4 |
| Techlite Pen Needle | 12 | $254 | $21 |
| Fenofibrate | 13 | $237 | $18 |
| Verapamil Er | 11 | $179 | $16 |
| Spironolactone | 12 | $123 | $10 |
2022: 42 drugs
| Eliquis | 91 | $92,559 | $1,017 |
| Entresto | 33 | $33,139 | $1,004 |
| Ranolazine Er | 120 | $22,176 | $185 |
| Nitroglycerin | 379 | $16,592 | $44 |
| Brilinta | 24 | $13,459 | $561 |
| Vascepa | 24 | $7,954 | $331 |
| Repatha Sureclick | 13 | $6,448 | $496 |
| Metoprolol | 337 | $5,028 | $15 |
| Rosuvastatin | 122 | $4,842 | $40 |
| Olmesartan-Hydrochlorothiazide | 34 | $3,925 | $115 |
| Isosorbide Mononitrate Er | 227 | $3,458 | $15 |
| Atorvastatin | 279 | $2,953 | $11 |
| Ezetimibe | 37 | $2,796 | $76 |
| Amiodarone | 20 | $2,434 | $122 |
| Losartan-Hydrochlorothiazide | 56 | $2,055 | $37 |
| Hydralazine | 149 | $2,019 | $14 |
| Nifedipine Er | 36 | $1,832 | $51 |
| Propranolol | 98 | $1,686 | $17 |
| Amlodipine Besylate | 181 | $1,630 | $9 |
| Carvedilol | 140 | $1,475 | $11 |
| Amlodipine Besylate-Benazepril | 97 | $1,277 | $13 |
| Cilostazol | 80 | $1,269 | $16 |
| Ramipril | 63 | $1,108 | $18 |
| Losartan | 117 | $965 | $8 |
| Olmesartan Medoxomil | 49 | $941 | $19 |
| Bumetanide | 16 | $940 | $59 |
| Clonidine | 88 | $903 | $10 |
| Lisinopril | 116 | $730 | $6 |
| Fenofibrate | 24 | $723 | $30 |
| Clopidogrel | 45 | $605 | $13 |
| Metoprolol | 105 | $590 | $6 |
| Chlorthalidone | 12 | $509 | $42 |
| Benazepril | 50 | $507 | $10 |
| Furosemide | 66 | $379 | $6 |
| Atenolol | 16 | $283 | $18 |
| Diltiazem 24hr Er (Cd) | 15 | $279 | $19 |
| Simvastatin | 28 | $271 | $10 |
| Terazosin | 11 | $246 | $22 |
| Doxazosin Mesylate | 12 | $201 | $17 |
| Spironolactone | 16 | $163 | $10 |
| Hydrochlorothiazide | 20 | $130 | $6 |
| Fenofibrate | 14 | $97 | $7 |
2021: 33 drugs
| Eliquis | 49 | $49,943 | $1,019 |
| Brilinta | 24 | $14,685 | $612 |
| Nitroglycerin | 303 | $12,191 | $40 |
| Entresto | 14 | $11,004 | $786 |
| Ranolazine Er | 45 | $9,118 | $203 |
| Amiodarone | 16 | $3,287 | $205 |
| Metoprolol | 218 | $2,831 | $13 |
| Atorvastatin | 177 | $1,889 | $11 |
| Ezetimibe | 36 | $1,624 | $45 |
| Rosuvastatin | 46 | $1,501 | $33 |
| Isosorbide Mononitrate Er | 112 | $1,204 | $11 |
| Nifedipine Er | 30 | $1,016 | $34 |
| Carvedilol | 110 | $895 | $8 |
| Amlodipine Besylate-Benazepril | 68 | $816 | $12 |
| Olmesartan-Hydrochlorothiazide | 18 | $719 | $40 |
| Amlodipine Besylate | 100 | $699 | $7 |
| Propranolol | 57 | $691 | $12 |
| Hydralazine | 50 | $622 | $12 |
| Losartan-Hydrochlorothiazide | 31 | $461 | $15 |
| Clopidogrel | 60 | $461 | $8 |
| Losartan | 53 | $441 | $8 |
| Olmesartan Medoxomil | 18 | $375 | $21 |
| Ramipril | 31 | $326 | $11 |
| Metoprolol | 55 | $324 | $6 |
| Cilostazol | 31 | $319 | $10 |
| Fenofibrate | 11 | $245 | $22 |
| Lisinopril | 37 | $228 | $6 |
| Furosemide | 43 | $213 | $5 |
| Clonidine | 35 | $213 | $6 |
| Benazepril | 29 | $197 | $7 |
| Simvastatin | 12 | $161 | $13 |
| Pravastatin | 11 | $124 | $11 |
| Hydrochlorothiazide | 26 | $99 | $4 |
2020: 27 drugs
| Eliquis | 42 | $22,695 | $540 |
| Ranolazine Er | 57 | $10,737 | $188 |
| Nitroglycerin | 144 | $5,569 | $39 |
| Vascepa | 20 | $4,807 | $240 |
| Rosuvastatin | 48 | $2,653 | $55 |
| Metoprolol | 111 | $1,639 | $15 |
| Ezetimibe | 40 | $896 | $22 |
| Atorvastatin | 118 | $772 | $7 |
| Isosorbide Mononitrate Er | 58 | $768 | $13 |
| Propranolol | 44 | $709 | $16 |
| Nifedipine Er | 20 | $594 | $30 |
| Cilostazol | 35 | $439 | $13 |
| Losartan | 53 | $349 | $7 |
| Hydralazine | 23 | $348 | $15 |
| Amlodipine Besylate-Benazepril | 39 | $324 | $8 |
| Carvedilol | 68 | $293 | $4 |
| Doxazosin Mesylate | 11 | $281 | $26 |
| Clonidine | 31 | $254 | $8 |
| Meclizine | 17 | $243 | $14 |
| Benazepril | 24 | $204 | $8 |
| Hydrochlorothiazide | 45 | $190 | $4 |
| Amlodipine Besylate | 74 | $176 | $2 |
| Clopidogrel | 30 | $172 | $6 |
| Amiodarone | 24 | $113 | $5 |
| Ramipril | 18 | $78 | $4 |
| Lisinopril | 30 | $76 | $3 |
| Metoprolol | 18 | $72 | $4 |
2019: 43 drugs
| Eliquis | 110 | $61,016 | $555 |
| Ranexa | 75 | $46,536 | $620 |
| Repatha Sureclick | 11 | $13,518 | $1,229 |
| Ranolazine Er | 37 | $9,728 | $263 |
| Brilinta | 17 | $8,780 | $516 |
| Vascepa | 33 | $7,517 | $228 |
| Nitroglycerin | 190 | $6,561 | $35 |
| Rosuvastatin | 174 | $6,462 | $37 |
| Metoprolol | 203 | $3,698 | $18 |
| Isosorbide Mononitrate Er | 185 | $3,111 | $17 |
| Atorvastatin | 231 | $2,205 | $10 |
| Niacin Er | 11 | $1,745 | $159 |
| Propranolol | 83 | $1,698 | $20 |
| Nifedipine Er | 39 | $1,585 | $41 |
| Olmesartan Medoxomil | 31 | $1,512 | $49 |
| Olmesartan-Amlodipine-Hctz | 12 | $1,430 | $119 |
| Hydralazine | 100 | $1,397 | $14 |
| Ezetimibe | 71 | $1,369 | $19 |
| Amlodipine Besylate-Benazepril | 70 | $1,359 | $19 |
| Carvedilol | 202 | $1,269 | $6 |
| Cilostazol | 76 | $1,051 | $14 |
| Amlodipine Besylate | 262 | $1,036 | $4 |
| Olmesartan-Hydrochlorothiazide | 28 | $970 | $35 |
| Fenofibrate | 28 | $952 | $34 |
| Ramipril | 96 | $861 | $9 |
| Doxazosin Mesylate | 26 | $600 | $23 |
| Amiodarone | 43 | $592 | $14 |
| Losartan | 99 | $482 | $5 |
| Benazepril | 58 | $471 | $8 |
| Clonidine | 69 | $441 | $6 |
| Clopidogrel | 71 | $437 | $6 |
| Fenofibrate | 16 | $365 | $23 |
| Meclizine | 24 | $295 | $12 |
| Losartan-Hydrochlorothiazide | 50 | $295 | $6 |
| Metoprolol | 84 | $287 | $3 |
| Prasugrel | 12 | $273 | $23 |
| Lisinopril | 54 | $266 | $5 |
| Furosemide | 48 | $190 | $4 |
| Irbesartan | 11 | $187 | $17 |
| Simvastatin | 38 | $174 | $5 |
| Atenolol | 30 | $166 | $6 |
| Hydrochlorothiazide | 53 | $148 | $3 |
| Pantoprazole | 15 | $89 | $6 |
2018: 63 drugs
| Ranexa | 241 | $139,688 | $580 |
| Eliquis | 178 | $101,370 | $569 |
| Ezetimibe | 125 | $21,557 | $172 |
| Nitroglycerin | 319 | $13,757 | $43 |
| Rosuvastatin | 284 | $13,408 | $47 |
| Xarelto | 17 | $11,126 | $654 |
| Metoprolol | 361 | $8,066 | $22 |
| Isosorbide Mononitrate Er | 416 | $7,552 | $18 |
| Entresto | 14 | $7,258 | $518 |
| Crestor | 27 | $6,473 | $240 |
| Diovan Hct | 16 | $6,278 | $392 |
| Brilinta | 12 | $5,194 | $433 |
| Propranolol | 230 | $4,812 | $21 |
| Vytorin | 14 | $4,787 | $342 |
| Plavix | 18 | $4,316 | $240 |
| Lotrel | 12 | $4,004 | $334 |
| Valsartan | 104 | $3,427 | $33 |
| Atorvastatin | 346 | $3,342 | $10 |
| Amlodipine Besylate-Benazepril | 151 | $2,944 | $19 |
| Niacin Er | 12 | $2,914 | $243 |
| Amiodarone | 73 | $2,761 | $38 |
| Hydralazine | 154 | $2,627 | $17 |
| Nifedipine Er | 74 | $2,566 | $35 |
| Vascepa | 13 | $2,418 | $186 |
| Omega-3 Acid Ethyl Esters | 32 | $2,342 | $73 |
| Olmesartan Medoxomil | 42 | $2,249 | $54 |
| Cilostazol | 150 | $2,236 | $15 |
| Ramipril | 214 | $2,001 | $9 |
| Amlodipine Besylate | 490 | $1,808 | $4 |
| Fenofibrate | 46 | $1,700 | $37 |
| Olmesartan-Amlodipine-Hctz | 16 | $1,667 | $104 |
| Carvedilol | 342 | $1,588 | $5 |
| Valsartan-Hydrochlorothiazide | 82 | $1,427 | $17 |
| Losartan | 231 | $1,399 | $6 |
| Doxazosin Mesylate | 51 | $1,357 | $27 |
| Benazepril | 178 | $1,221 | $7 |
| Esomeprazole Magnesium | 12 | $1,173 | $98 |
| Fenofibrate | 30 | $1,146 | $38 |
| Clopidogrel | 173 | $1,055 | $6 |
| Benazepril-Hydrochlorothiazide | 21 | $1,022 | $49 |
| Olmesartan-Hydrochlorothiazide | 30 | $1,014 | $34 |
| Metoprolol | 238 | $813 | $3 |
| Fenofibrate | 16 | $764 | $48 |
| Enalapril Maleate | 23 | $741 | $32 |
| Digoxin | 18 | $701 | $39 |
| Voltaren | 11 | $605 | $55 |
| Isosorbide Dinitrate | 14 | $595 | $42 |
| Losartan-Hydrochlorothiazide | 82 | $542 | $7 |
| Lisinopril | 100 | $525 | $5 |
| Pravastatin | 28 | $514 | $18 |
| Atenolol | 76 | $474 | $6 |
| Simvastatin | 96 | $456 | $5 |
| Clonidine | 88 | $437 | $5 |
| Hydrochlorothiazide | 94 | $394 | $4 |
| Amlodipine-Valsartan | 12 | $350 | $29 |
| Furosemide | 114 | $305 | $3 |
| Prasugrel | 12 | $278 | $23 |
| Meclizine | 28 | $254 | $9 |
| Gemfibrozil | 19 | $199 | $10 |
| Pantoprazole | 34 | $164 | $5 |
| Ranitidine | 13 | $69 | $5 |
| Escitalopram | 11 | $45 | $4 |
| Gabapentin | 11 | $21 | $2 |
2017: 65 drugs
| Ranexa | 224 | $117,694 | $525 |
| Eliquis | 161 | $81,961 | $509 |
| Zetia | 42 | $21,503 | $512 |
| Rosuvastatin | 278 | $15,966 | $57 |
| Ezetimibe | 80 | $15,754 | $197 |
| Nitroglycerin | 216 | $9,636 | $45 |
| Metoprolol | 328 | $8,754 | $27 |
| Isosorbide Mononitrate Er | 419 | $8,386 | $20 |
| Benicar | 22 | $8,337 | $379 |
| Crestor | 25 | $6,618 | $265 |
| Bystolic | 17 | $5,712 | $336 |
| Entresto | 13 | $5,557 | $427 |
| Valsartan | 150 | $5,447 | $36 |
| Propranolol | 202 | $5,177 | $26 |
| Diovan Hct | 13 | $4,662 | $359 |
| Benicar Hct | 14 | $4,512 | $322 |
| Brilinta | 11 | $4,385 | $399 |
| Nexium | 16 | $4,079 | $255 |
| Atorvastatin | 326 | $3,538 | $11 |
| Lotrel | 11 | $3,455 | $314 |
| Amiodarone | 44 | $3,425 | $78 |
| Olmesartan-Amlodipine-Hctz | 22 | $2,588 | $118 |
| Plavix | 13 | $2,567 | $197 |
| Nifedipine Er | 71 | $2,414 | $34 |
| Olmesartan Medoxomil | 32 | $2,272 | $71 |
| Omega-3 Acid Ethyl Esters | 18 | $2,246 | $125 |
| Amlodipine Besylate-Benazepril | 91 | $2,185 | $24 |
| Hydralazine | 88 | $1,857 | $21 |
| Cilostazol | 149 | $1,854 | $12 |
| Carvedilol | 357 | $1,772 | $5 |
| Amlodipine Besylate | 403 | $1,753 | $4 |
| Valsartan-Hydrochlorothiazide | 82 | $1,668 | $20 |
| Fenofibrate | 33 | $1,609 | $49 |
| Doxazosin Mesylate | 64 | $1,598 | $25 |
| Ramipril | 165 | $1,450 | $9 |
| Nitrostat | 22 | $1,392 | $63 |
| Digoxin | 30 | $1,347 | $45 |
| Isosorbide Dinitrate | 23 | $1,307 | $57 |
| Fenofibrate | 26 | $1,258 | $48 |
| Clopidogrel | 198 | $1,191 | $6 |
| Benazepril-Hydrochlorothiazide | 26 | $1,123 | $43 |
| Benazepril | 126 | $1,046 | $8 |
| Losartan | 135 | $817 | $6 |
| Metoprolol | 222 | $761 | $3 |
| Clonidine | 99 | $721 | $7 |
| Amlodipine-Valsartan | 13 | $712 | $55 |
| Olmesartan-Hydrochlorothiazide | 15 | $676 | $45 |
| Enalapril Maleate | 19 | $662 | $35 |
| Simvastatin | 94 | $537 | $6 |
| Hydrochlorothiazide | 80 | $452 | $6 |
| Pravastatin | 33 | $435 | $13 |
| Diltiazem 24hr Er | 14 | $408 | $29 |
| Losartan-Hydrochlorothiazide | 49 | $396 | $8 |
| Fenofibrate | 13 | $366 | $28 |
| Lisinopril | 76 | $358 | $5 |
| Furosemide | 88 | $338 | $4 |
| Atenolol | 43 | $238 | $6 |
| Gemfibrozil | 16 | $212 | $13 |
| Potassium Chloride | 13 | $211 | $16 |
| Verapamil Er | 16 | $201 | $13 |
| Diltiazem | 13 | $174 | $13 |
| Sotalol | 13 | $129 | $10 |
| Spironolactone | 11 | $46 | $4 |
| Naproxen | 13 | $40 | $3 |
| Lovastatin | 14 | $40 | $3 |
2016: 51 drugs
| Ranexa | 141 | $65,412 | $464 |
| Crestor | 183 | $54,196 | $296 |
| Eliquis | 119 | $43,912 | $369 |
| Zetia | 85 | $28,360 | $334 |
| Benicar | 67 | $19,316 | $288 |
| Nitrostat | 170 | $9,051 | $53 |
| Metoprolol | 312 | $7,403 | $24 |
| Benicar Hct | 23 | $6,977 | $303 |
| Isosorbide Mononitrate Er | 318 | $5,761 | $18 |
| Propranolol | 212 | $5,244 | $25 |
| Rosuvastatin | 61 | $4,785 | $78 |
| Doxazosin Mesylate | 109 | $3,461 | $32 |
| Valsartan | 98 | $3,407 | $35 |
| Bystolic | 12 | $3,179 | $265 |
| Plavix | 14 | $3,159 | $226 |
| Nifedipine Er | 80 | $2,815 | $35 |
| Atorvastatin | 242 | $2,559 | $11 |
| Nitroglycerin | 50 | $2,268 | $45 |
| Cilostazol | 189 | $2,192 | $12 |
| Fenofibrate | 33 | $2,109 | $64 |
| Amiodarone | 28 | $2,023 | $72 |
| Hydralazine | 97 | $2,000 | $21 |
| Valsartan-Hydrochlorothiazide | 77 | $1,724 | $22 |
| Ramipril | 140 | $1,507 | $11 |
| Amlodipine Besylate | 265 | $1,304 | $5 |
| Amlodipine Besylate-Benazepril | 56 | $1,239 | $22 |
| Benazepril | 108 | $1,028 | $10 |
| Carvedilol | 196 | $993 | $5 |
| Fenofibrate | 21 | $898 | $43 |
| Pravastatin | 39 | $776 | $20 |
| Clopidogrel | 151 | $766 | $5 |
| Losartan | 107 | $714 | $7 |
| Nifedical Xl | 30 | $661 | $22 |
| Verapamil Er | 28 | $629 | $22 |
| Clonidine | 57 | $615 | $11 |
| Enalapril Maleate | 16 | $539 | $34 |
| Fenofibric Acid | 12 | $532 | $44 |
| Amlodipine-Valsartan | 12 | $496 | $41 |
| Pentoxifylline | 28 | $482 | $17 |
| Metoprolol | 117 | $438 | $4 |
| Losartan-Hydrochlorothiazide | 51 | $434 | $9 |
| Simvastatin | 65 | $422 | $6 |
| Hydrochlorothiazide | 87 | $383 | $4 |
| Easy Touch Pen Needle | 13 | $346 | $27 |
| Furosemide | 58 | $256 | $4 |
| Diltiazem 24hr Cd | 15 | $238 | $16 |
| Lisinopril | 64 | $188 | $3 |
| Sotalol | 14 | $147 | $10 |
| Atenolol | 36 | $126 | $4 |
| Warfarin | 16 | $82 | $5 |
| Famotidine | 11 | $27 | $2 |
2015: 51 drugs
| Ranexa | 148 | $60,006 | $405 |
| Crestor | 162 | $46,423 | $287 |
| Eliquis | 60 | $20,131 | $336 |
| Zetia | 58 | $15,868 | $274 |
| Benicar | 50 | $13,560 | $271 |
| Pradaxa | 16 | $7,450 | $466 |
| Nitrostat | 208 | $7,423 | $36 |
| Isosorbide Mononitrate Er | 244 | $7,332 | $30 |
| Metoprolol | 225 | $5,855 | $26 |
| Plavix | 16 | $4,671 | $292 |
| Diovan | 15 | $4,573 | $305 |
| Coreg Cr | 20 | $4,428 | $221 |
| Lantus Solostar | 11 | $4,132 | $376 |
| Valsartan | 58 | $3,496 | $60 |
| Doxazosin Mesylate | 108 | $3,442 | $32 |
| Hydralazine | 154 | $3,091 | $20 |
| Propranolol | 123 | $2,894 | $24 |
| Nifedipine Er | 54 | $2,687 | $50 |
| Benicar Hct | 11 | $2,680 | $244 |
| Fenofibrate | 32 | $2,662 | $83 |
| Atorvastatin | 153 | $2,444 | $16 |
| Isosorbide Dinitrate | 23 | $1,944 | $85 |
| Cilostazol | 130 | $1,784 | $14 |
| Bystolic | 15 | $1,711 | $114 |
| Valsartan-Hydrochlorothiazide | 77 | $1,465 | $19 |
| Amlodipine Besylate | 256 | $1,421 | $6 |
| Amiodarone | 32 | $1,262 | $39 |
| Verapamil Er | 61 | $1,092 | $18 |
| Amlodipine Besylate-Benazepril | 47 | $1,017 | $22 |
| Clopidogrel | 124 | $1,002 | $8 |
| Carvedilol | 146 | $915 | $6 |
| Digoxin | 17 | $894 | $53 |
| Nifedical Xl | 43 | $833 | $19 |
| Ramipril | 66 | $735 | $11 |
| Pravastatin | 24 | $660 | $27 |
| Benazepril | 63 | $607 | $10 |
| Fenofibric Acid | 12 | $533 | $44 |
| Pentoxifylline | 16 | $498 | $31 |
| Clonidine | 39 | $440 | $11 |
| Metoprolol | 102 | $365 | $4 |
| Losartan | 51 | $358 | $7 |
| Terazosin | 31 | $326 | $11 |
| Simvastatin | 53 | $318 | $6 |
| Easy Touch Pen Needle | 11 | $300 | $27 |
| Losartan-Hydrochlorothiazide | 14 | $209 | $15 |
| Hydrochlorothiazide | 40 | $188 | $5 |
| Lisinopril | 44 | $185 | $4 |
| Gemfibrozil | 13 | $185 | $14 |
| Atenolol | 25 | $131 | $5 |
| Furosemide | 21 | $105 | $5 |
| Lovastatin | 13 | $73 | $6 |
2014: 53 drugs
| Crestor | 150 | $35,525 | $237 |
| Ranexa | 58 | $22,418 | $387 |
| Diovan | 72 | $14,249 | $198 |
| Eliquis | 26 | $8,501 | $327 |
| Metoprolol | 206 | $8,234 | $40 |
| Benicar | 35 | $8,122 | $232 |
| Welchol | 15 | $6,756 | $450 |
| Zetia | 27 | $6,618 | $245 |
| Isosorbide Mononitrate Er | 195 | $6,532 | $33 |
| Valsartan-Hydrochlorothiazide | 95 | $4,833 | $51 |
| Xarelto | 12 | $4,636 | $386 |
| Nitrostat | 153 | $4,067 | $27 |
| Tribenzor | 12 | $2,630 | $219 |
| Plavix | 12 | $2,384 | $199 |
| Nifedipine Er | 60 | $2,351 | $39 |
| Amlodipine Besylate-Benazepril | 71 | $2,269 | $32 |
| Hydralazine | 92 | $2,152 | $23 |
| Doxazosin Mesylate | 64 | $2,013 | $31 |
| Carvedilol | 178 | $1,702 | $10 |
| Cilostazol | 57 | $1,684 | $30 |
| Fenofibrate | 14 | $1,653 | $118 |
| Nitroglycerin | 12 | $1,641 | $137 |
| Atorvastatin | 99 | $1,506 | $15 |
| Isosorbide Dinitrate | 27 | $1,497 | $55 |
| Ramipril | 80 | $1,490 | $19 |
| Clopidogrel | 135 | $1,465 | $11 |
| Digox | 28 | $1,346 | $48 |
| Bystolic | 15 | $1,309 | $87 |
| Propranolol | 79 | $866 | $11 |
| Nifedical Xl | 26 | $799 | $31 |
| Amlodipine Besylate | 156 | $748 | $5 |
| Benazepril | 44 | $585 | $13 |
| Simvastatin | 88 | $537 | $6 |
| Fenofibrate | 11 | $518 | $47 |
| Fenofibric Acid | 11 | $503 | $46 |
| Clonidine | 49 | $468 | $10 |
| Niacor | 12 | $404 | $34 |
| Digoxin | 11 | $394 | $36 |
| Amiodarone | 12 | $356 | $30 |
| Metolazone | 13 | $340 | $26 |
| Lisinopril | 47 | $282 | $6 |
| Montelukast | 13 | $265 | $20 |
| Losartan | 26 | $250 | $10 |
| Terazosin | 23 | $250 | $11 |
| Metoprolol | 52 | $234 | $5 |
| Losartan-Hydrochlorothiazide | 22 | $219 | $10 |
| Atenolol | 41 | $188 | $5 |
| Sotalol | 13 | $187 | $14 |
| Hydrochlorothiazide | 29 | $154 | $5 |
| Warfarin | 14 | $129 | $9 |
| Spironolactone | 21 | $120 | $6 |
| Furosemide | 34 | $120 | $4 |
| Famotidine | 14 | $77 | $5 |
2013: 43 drugs
| Crestor | 158 | $30,296 | $192 |
| Diovan | 132 | $23,471 | $178 |
| Zetia | 98 | $19,745 | $201 |
| Ranexa | 42 | $12,760 | $304 |
| Clopidogrel | 146 | $10,136 | $69 |
| Valsartan-Hydrochlorothiazide | 92 | $8,126 | $88 |
| Isosorbide Mononitrate Er | 320 | $7,798 | $24 |
| Metoprolol | 224 | $7,689 | $34 |
| Benicar | 34 | $6,046 | $178 |
| Amlodipine Besylate-Benazepril | 103 | $5,611 | $54 |
| Diovan Hct | 28 | $5,429 | $194 |
| Welchol | 13 | $4,614 | $355 |
| Niaspan | 17 | $3,533 | $208 |
| Nitrostat | 160 | $3,527 | $22 |
| Nifedipine Er | 64 | $3,160 | $49 |
| Pradaxa | 11 | $2,827 | $257 |
| Cilostazol | 102 | $2,669 | $26 |
| Atorvastatin | 92 | $2,367 | $26 |
| Fenofibrate | 19 | $2,231 | $117 |
| Carvedilol | 182 | $1,943 | $11 |
| Hydralazine | 61 | $1,923 | $32 |
| Doxazosin Mesylate | 84 | $1,660 | $20 |
| Amiodarone | 26 | $1,332 | $51 |
| Ramipril | 91 | $1,222 | $13 |
| Amlodipine Besylate | 182 | $1,215 | $7 |
| Losartan | 54 | $832 | $15 |
| Clonidine | 70 | $713 | $10 |
| Simvastatin | 73 | $631 | $9 |
| Benazepril | 56 | $585 | $10 |
| Propranolol | 79 | $514 | $7 |
| Digox | 39 | $498 | $13 |
| Nifedical Xl | 20 | $431 | $22 |
| Verapamil Er | 22 | $423 | $19 |
| Niacor | 15 | $375 | $25 |
| Losartan-Hydrochlorothiazide | 25 | $338 | $14 |
| Furosemide | 40 | $296 | $7 |
| Pravastatin | 17 | $256 | $15 |
| Sotalol | 17 | $228 | $13 |
| Metoprolol | 44 | $225 | $5 |
| Lisinopril | 30 | $197 | $7 |
| Atenolol | 21 | $180 | $9 |
| Hydrochlorothiazide | 18 | $125 | $7 |
| Spironolactone | 13 | $83 | $6 |
Money from drug and device companies
$80 in 2025
| 2025 | 3 | 3 | None | $80 |
| 2024 | 5 | 7 | None | $155 |
| 2023 | 3 | 3 | None | $115 |
| 2022 | 3 | 5 | None | $327 |
| 2021 | 4 | 9 | None | $619 |
| 2020 | 5 | 6 | None | $288 |
| 2019 | 11 | 67 | None | $1,527 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Jot Dx | $34 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $26 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $21 | 1 payment
|
See all 3 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-12 | Jardiance | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-18 | Kerendia | $26 |
| Abbott Laboratories | Meals · 2025-10-31 | Jot Dx | $34 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $155
| Novartis Pharmaceuticals | Leqvio | $63 | 3 payments
|
| Amgen | Repatha | $32 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $23 | 1 payment
|
| Abbott Laboratories | Merlin@Home | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $17 | 1 payment
|
2023: $115
| Abbott Laboratories | Aveir | $80 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $21 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $13 | 1 payment
|
2022: $327
| Abbott Laboratories | Jot Dx | $298 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $15 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $14 | 1 payment
|
2021: $619
| Abbott Laboratories | Fortify Assura, Ellipse Icd | $522 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $43 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $39 | 2 payments
|
| Pfizer | Eliquis | $14 | 1 payment
|
2020: $288
| Abbott Laboratories | Fortify Assura, Ellipse Icd | $221 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $20 | 1 payment
|
| Pfizer | Vyndaqel | $19 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $16 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $13 | 1 payment
|
2019: $1,527
| Abbott Laboratories | Fortify Assura, Ellipse Icd | $689 | 6 payments
|
| Novartis Pharmaceuticals | Entresto | $186 | 13 payments
|
| Gilead Sciences | None | $177 | 20 payments
|
| Amgen | Corlanor | $119 | 6 payments
|
| Medtronic Vascular | Closurefast | $99 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $70 | 5 payments
|
| Pfizer | Vyndaqel | $65 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $46 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $41 | 3 payments
|
| Sanofi-Aventis U.S. | Praluent | $18 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $17 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Vifor (International) Ltd. · Pat-Cr-302 · 2021 | Their institution | $15,050 |
Checkups this office reported
1 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 1,070 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- Implementation of a Personal Protective Equipment (PPE) Plan
- Offers telehealth visits
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
- Exempt from support electronic referral loops by receiving and reconciling health information
- Exempt from support electronic referral loops by sending health information
Professional record
- NPI
- 1619964095
- Licence
- CA C42324California C42324: Current · expires 2028-06-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00C423240
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Internal medicine (207R00000X)
- Mailing address
- Po Box 3146, Chatsworth, CA, 91313
- NPI first listed
- 2005-09-30
- NPI last updated
- 2013-11-12
This is when the NPI record was last certified, not a medical board exam.